Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®
- Sponsor
- Federico II University
- Study ID
- NCT04313270
- Status
- Unknown
Conditions
- Hypercholesterolemia, Familial
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Evolocumab — DRUG12 weeks of treatment with Evolocumab
Study Details
Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events. The investigators will evaluate changes in lipid profile, oxidation markers and subclinical atherosclerosis in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with a PCSK-9 inhibitor, Evolocumab®.
Key Dates
- Start date
- Dec 1, 2017
- Status verified
- Mar 2021
- Primary completion
- Dec 1, 2022
- Completion
- Dec 1, 2025
Study Design
- Enrollment
- 25 participants (estimated)
Arms
- Arm: Patients with FH starting a treatment with Evolocumab®
Primary Outcome Measure
Subclinical atherosclerosis [ Time Frame: 12 weeks ]